Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/9/2019
SIETES contiene 92806 citas

 
 
 1 a 10 de 10 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Anónimo. Reacciones adversas a medicamentos registradas en el Conjunto Mínimo Básico de Datos (CMBD). Boletín de Farmacovigilancia de la Región de Murcia 2011;23:1-2. [Ref.ID 92092]
2.
Engel PJ, Johnson H. High-output heart failure associated with anagrelide therapy for essential thrombocytosis. Ann Intern Med 2005;143:311-3. [Ref.ID 74647]
3. Cita con resumen
Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003;362:523-6. [Ref.ID 67177]
4.
Liautard C, Correa Nunes AM, Vial T, Chatillon F, Guy C, Ollagnier M, Descotes J. Low-molecular-weight heparins and thrombocytosis. Ann Pharmacother 2002;36:1351-4. [Ref.ID 63350]
5.
Brooks WG, Stanley DD, Goode JVKR. Role of anagrelide in the treatment of thrombocytosis. Ann Pharmacother 1999;33:1116-8,1121. [Ref.ID 47734]
6.
Gürsoy M, Haznedaroglu IC, Çelik I, Sayinalp N, Özcebe O I, Dündar SV. Agranulocytosis, plasmacytosis, and thrombocytosis followed by a leukemoid reaction due to acute acetaminophen toxicity. Ann Pharmacother 1996;30:762-5. [Ref.ID 28725]
7.
Rizzieri D A, Wong WM, Gockerman JP. Thrombocytosis associated with low-molecular-weight heparin. Ann Intern Med 1996;125:157. [Ref.ID 28500]
8.
Dasgupta B. Haemotological effects of interleukin-1. Lancet 1990;336:1506. [Ref.ID 15793]
9.
Currie WR, Kaegi A. Rebound thrombocytosis after alcohol abuse. Lancet 1977;1:1369. [Ref.ID 3035]
Seleccionar todas
 
 1 a 10 de 10